5-MeO-isoDMT, or 5-OMe-isoDMT, also known as 5-methoxy-N,N-dimethylisotryptamine, is a putatively non-hallucinogenic serotonin 5-HT<sub>2A</sub> receptor agonist and psychoplastogen of the isotryptamine group. It is the isotryptamine analogue of the non-hallucinogenic 6-MeO-DMT and is a positional isomer of the psychedelic 6-MeO-isoDMT.
The drug does not substitute for serotonergic psychedelics in animal drug discrimination tests and does not produce the head-twitch response, a behavioral of psychedelic effects, at any dose. Hence, it appears to be non-hallucinogenic. On the other hand, 5-MeO-isoDMT has comparable psychoplastogenic potency and effects compared to the psychedelic 5-MeO-DMT. These effects are blocked by the serotonin 5-HT<sub>2A</sub> receptor antagonist ketanserin. Certain analogues and derivatives of 5-MeO-isoDMT, like isoDMT and the ñ-methylated zalsupindole (DLX-001; AAZ-A-154; (R)-5-MeO-ñ-methyl-isoDMT), likewise produce no head-twitch response, whereas 6-MeO-isoDMT produces a reduced head-twitch response. Hence, these analogues appear to be less or fully non-hallucinogenic similarly to 5-MeO-isoDMT. In addition, like 5-MeO-isoDMT, they retain potent psychoplastogenic effects.
5-MeO-isoDMT was first described in the scientific literature by 1984. It was subsequently further characterized in 2020. Confusingly, the drug has been referred to as "6-MeO-isoDMT" (or rather "6-OMe-isoDMT") in some publications.